PE20170769A1 - Procedimiento novedoso para la purificacion de rhu-gcsf - Google Patents

Procedimiento novedoso para la purificacion de rhu-gcsf

Info

Publication number
PE20170769A1
PE20170769A1 PE2017000070A PE2017000070A PE20170769A1 PE 20170769 A1 PE20170769 A1 PE 20170769A1 PE 2017000070 A PE2017000070 A PE 2017000070A PE 2017000070 A PE2017000070 A PE 2017000070A PE 20170769 A1 PE20170769 A1 PE 20170769A1
Authority
PE
Peru
Prior art keywords
gcsf
purification
previous step
rhu
isolation
Prior art date
Application number
PE2017000070A
Other languages
English (en)
Inventor
Arjun Raghuwanshi
Shrawan Kumar Singh
Nidhiben Thaker
Shagun Shankar
Pavan Kardile
Sanjay Singh
Original Assignee
Gennova Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gennova Biopharmaceuticals Ltd filed Critical Gennova Biopharmaceuticals Ltd
Publication of PE20170769A1 publication Critical patent/PE20170769A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion se refiere a un procedimiento para el aislamiento y la purificacion del Factor estimulante de colonias de granulocitos (GCSF) que comprende: i) producir GCSF humano recombinante (rhu-GCSF) mediante fermentacion de alta densidad celular de E. coli y aislamiento de cuerpos de inclusion; ii) solubilizar cuerpos de inclusion obtenidos de la etapa (i) para liberar GCSF; iii) replegar la proteina GCSF obtenida en la etapa anterior; iv) clarificacion y purificacion de la proteina GCSF obtenida en la etapa anterior; v) opcionalmente conjugar GCSF purificado obtenido de la etapa anterior con polietilenglicol (PEG); y vi) opcionalmente purificar el GCSF conjugado (pegilado) obtenido en la etapa anterior usando cromatografia de intercambio cationico. Tambien se refiere a una composicion farmaceutica que comprende dicho GCSF pegilado obtenido. Dicho procedimiento es escalable e industrialmente viable para la purificacion de GCSF humano recombinante
PE2017000070A 2014-07-14 2015-07-13 Procedimiento novedoso para la purificacion de rhu-gcsf PE20170769A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2289MU2014 2014-07-14

Publications (1)

Publication Number Publication Date
PE20170769A1 true PE20170769A1 (es) 2017-07-04

Family

ID=55079140

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2022000247A PE20220371A1 (es) 2014-07-14 2015-07-13 PROCEDIMIENTO NOVEDOSO PARA LA PURIFICACION DE rHU-GCSF
PE2017000070A PE20170769A1 (es) 2014-07-14 2015-07-13 Procedimiento novedoso para la purificacion de rhu-gcsf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2022000247A PE20220371A1 (es) 2014-07-14 2015-07-13 PROCEDIMIENTO NOVEDOSO PARA LA PURIFICACION DE rHU-GCSF

Country Status (12)

Country Link
US (1) US10519209B2 (es)
EP (1) EP3169697B1 (es)
JP (1) JP6742300B2 (es)
AU (1) AU2015291123C1 (es)
CL (1) CL2017000087A1 (es)
CO (1) CO2017001387A2 (es)
EA (1) EA035448B1 (es)
MX (1) MX2017000467A (es)
NZ (1) NZ728662A (es)
PE (2) PE20220371A1 (es)
SA (1) SA517380723B1 (es)
WO (1) WO2016009451A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
CN109840410B (zh) * 2017-12-28 2021-09-21 中国科学院计算技术研究所 一种进程内数据隔离与保护的方法和系统
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
JP2022529811A (ja) * 2019-04-24 2022-06-24 タンベックス バイオファーマ ユーエスエー，インコーポレイティド 顆粒球コロニー刺激因子を調製するためのプロセス
US20230002441A1 (en) * 2019-12-03 2023-01-05 Indian Institute Of Technology Delhi A process for preparation of pegylated therapeutic proteins
WO2022167886A1 (en) * 2021-02-04 2022-08-11 Intas Pharmaceuticals Ltd. An improved peg-gcsf purification process having dual ufdf
WO2022245259A1 (ru) * 2021-05-18 2022-11-24 Акционерное общество "ГЕНЕРИУМ" Способ промышленной очистки ромиплостима

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ218336A (en) 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
ES2297889T3 (es) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US6653098B1 (en) * 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
FR2796071B1 (fr) 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes
CN1663962A (zh) * 2004-03-01 2005-09-07 重庆富进生物医药有限公司 重组人粒细胞集落刺激因子及其化学修饰物的一步纯化工艺
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
DE102005033250A1 (de) * 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
WO2007147019A2 (en) * 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
WO2008096370A2 (en) 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
PT2341061E (pt) * 2009-12-31 2013-11-05 Arven Ilac Sanayi Ve Ticaret As Um processo novo para a preparação de g-csf (fator de estimulação de colónias de granulócitos)
CN102234310B (zh) * 2010-04-30 2017-02-08 杭州九源基因工程有限公司 一种聚乙二醇修饰蛋白的分离纯化方法
RU2446173C1 (ru) * 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
KR101831300B1 (ko) * 2010-10-29 2018-02-23 한미사이언스 주식회사 재조합 대장균으로부터 인간 과립구 콜로니 자극인자를 정제하는 방법
CN102485742A (zh) 2010-12-02 2012-06-06 山东新时代药业有限公司 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子的制备及分离纯化方法
CA2826114A1 (en) * 2011-02-01 2012-08-09 Fate Therapeutics, Inc. Cardiotrophin related molecules for enhanced therapeutics
US9422354B2 (en) * 2012-06-19 2016-08-23 Indian Institute Of Technology Delhi Process for purification of recombinant granulocyte colony stimulating factor (rHu GCSF)

Also Published As

Publication number Publication date
CO2017001387A2 (es) 2017-05-10
US20170210784A1 (en) 2017-07-27
EP3169697B1 (en) 2024-10-23
NZ728662A (en) 2021-01-29
PE20220371A1 (es) 2022-03-16
AU2015291123A1 (en) 2017-02-23
JP2017526649A (ja) 2017-09-14
EP3169697A2 (en) 2017-05-24
US10519209B2 (en) 2019-12-31
WO2016009451A3 (en) 2016-05-19
EA035448B1 (ru) 2020-06-17
AU2015291123B2 (en) 2020-03-12
JP6742300B2 (ja) 2020-08-19
MX2017000467A (es) 2017-07-28
CL2017000087A1 (es) 2018-05-18
AU2015291123C1 (en) 2020-12-10
BR112017000704A2 (pt) 2017-11-14
EP3169697A4 (en) 2017-11-08
EA201700058A1 (ru) 2017-07-31
WO2016009451A2 (en) 2016-01-21
SA517380723B1 (ar) 2021-05-18

Similar Documents

Publication Publication Date Title
PE20170769A1 (es) Procedimiento novedoso para la purificacion de rhu-gcsf
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
AR099289A1 (es) Proteínas de fusión de interleucina-2 y usos de las mismas
ECSP18041733A (es) Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
AR067666A1 (es) Proteinas de union al antigeno del receptor de il-18
CL2017003218A1 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
AR072000A1 (es) Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
BR112012021329A2 (pt) anticorpo monoclonal anti-tnf-<244> completamente humano, método de preparação e uso do mesmo.
DOP2016000127A (es) Inhibidores de quinasa relacionada con la tropomiosina (trk).
EA201270571A1 (ru) Человеческие il-23-антигенсвязывающие белки
EA201290567A1 (ru) Получение гетерологичных полипептидов в микроводорослях, внеклеточные микроводорослевые тельца, композиции и способы их получения и применения
ES2481641T3 (es) Uso de receptor inmunosupresor
SV2011003828A (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
AR092076A1 (es) Proteinas homodimericas
BR112014008700A2 (pt) composições úteis no tratamento de nefropatia e processos para preparação das mesmas
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
CO6400150A2 (es) Proteína de enlace de il-13
PE20150996A1 (es) Etanercept correctamente plegado de alta pureza y excelente rendimiento
GT200900126A (es) Novedosos anticuerpos antiproliferacion
AR107735A1 (es) MOLÉCULAS DE ANTICUERPOS MULTIESPECÍFICAS QUE TIENEN ESPECIFICIDAD POR FACTOR DE NECROSIS TUMORAL a (TNF-a), INTERLEUCINAS: IL-17A E IL-17F
AR101735A1 (es) Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro)
PE20181176A1 (es) Composiciones biofarmaceuticas
EA201290684A1 (ru) Способ получения биологически активного рекомбинантного г-ксф человека